TherVacB – A THERAPEUTIC VACCINE TO CURE HEPATITIS B
European Commission and TherVacB join forces
The role of viral hepatitis as a public health threat has long been underestimated. Only very recently, the United Nations in their “2030 Agenda for Sustainable Development” called for international action to combat viral hepatitis and reduce the disease burden. The major killer is the hepatitis B virus (HBV) causing liver cirrhosis and liver cancer. Worldwide 880,000 humans die each year from the consequences of an HBV infection.
A prophylactic vaccine is available to prevent HBV infection, but more than 3% of the world’s population (about 260 million humans) are chronically infected and do not profit from that vaccine anymore. For those suffering from chronic hepatitis B, until today no curative treatment option exists.
The European Commission therefore selected the project TherVacB led by Helmholtz Zentrum München for a five-year funding within the Horizon 2020 program.
A consortium of leading virologists, immunologists and physicians specialized in treating viral hepatitis, will use a newly designed therapeutic vaccine, TherVacB, as an immunotherapy to cure HBV. TherVacB will be evaluated in a three-year clinical trial starting in 2022 conducted in Europe and in Africa. Integration of a partner site in Tanzania shall help building local capacities for diagnosing and treating hepatitis B and support an important goal of the consortium – to raise awareness for hepatitis B.
About TherVacB
For Patients
TherVacB Team
Partners
European countries
Project duration (months)
Happy World Hepatitis Day 2022!
Globally, 325 million people live with hepatitis, one of the most neglected diseases. On World Hepatitis Day 2022, the TherVacB project coordinator, Prof. Ulrike Protzer, joins the collective voices from across the world to raise awareness about Hepatitis B (HBV) and...
European Testing Week, 22-29 November 2021
Get your one-off screening for hepatitis B from your GP in Germany Hepatitis B can be treated well at an early stage, hepatitis C can even be cured. In Germany, like in other countries and regions of the world, many people affected are unaware of their infection....
HBV Cure Research Community Webinar, 24th November 2021
An online discussion for the HBV community on scientific progress in Europe towards a cure features the European HBV Patient Registry. The International Coalition for the Elimination of HBV, ICE-HBV, in partnership with Liver Patients International open the...
Animation movie
Enjoy our animation movie to understand the mission and approach of the TherVacB project!
TherVacB Publications
Find here scientific publications and technical articles from TherVacB project partners.
Read more about chronic hepatitis B, the virus, screening and testing for hepatitis C and B, therapeutic vaccination, and cure research.
All you need to know to understand Hepatitis B cure research – The HBV Cure FAQs
Watch the growing collection of short videos answering key questions on cure research raised by people living with Hepatitis B (HBV). The collection is a product of an international consortium of organizations, expert institutions and research projects working in and around Hepatitis B. Actively involved are ICE-HBV, Hepatitis B Foundation, World Hepatitis Alliance, HepBCommunity.org, Australian Centre for Hepatitis Virology, IP-cure-B, the Canadian HBV Network and TherVacB.
#WorldHepatitisDay may be over, but the need to spread awareness about #hepatitisB continues. Listen to Dayo’s story from #Nigeria about the need to take care of your health and ask loved ones to get vaccinated.
#BtheVoice Dayo's story from Nigeria, Hepatitis B Foundation
Almost 300 million people worldwide, including 20 million Nigerians, have chronic hepatitis B. Dayo is from Nigeria ...
ow.ly
August is #NationalImmunizationAwarenessMonth! #HepatitisB & #hepatitisD are both preventable diseases - the #vaccine is the best prevention for both viruses. Find resources & everything you need to know about the #hepB & #hepD vaccine at http://ow.ly/ZTrn50K5ogj
#NIAM22
🗓️It's today!
Join the @GlobalHep event today!
Discuss with speakers and share your experience as part of the #HepatitisB birth #dose community of practice in the #African region.
#worldhepatitisday_2022 #GlobalHealth #NoHep
Happening today Tuesday 3-5pm EAT; the Hepatitis Aid Organization will be speaking too, register in advance here @GlobalHep
https://taskforce-org.zoom.us/meeting/register/tZctdumhrDIoGNIp8M16Ww_Z_QJ4JObkKXYY
Evaluated #biomarkers are key to developing 🆕 #therapies. Our researchers @UlrikeProtzer @maini_lab @florian_bommel contributed to this important roadmap paving the way for the future of #chronic #HBVcure beyond @TherVacB_EU
@DZIF_🗞️➡️https://bit.ly/3BqgiLP
#LiverTwitter
Our #HBV Serum Biomarkers article is now online at @NatRevGastroHep. This was an important review, culminating almost 2 years work since the 2020 Serum Biomarkers workshops online. #WorldHepatitisDay
Full article & workshop recordings here: https://ice-hbv.org/now-published-hbv-serum-biomarkers-article-in-nature-reviews-gastroenterology-hepatology/
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 848223.